Arai et al. assessed the prognostic factors in 73 non-metastatic and metastatic prostate cancer patients treated with ADT and found that the patients who had a decrease in PSA levels of 80% or more within one month after the beginning of therapy experienced significantly longer free of disease progression [17]. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.